Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 19 - Drugs for skeletal disorders
Patents for A61P 19 - Drugs for skeletal disorders (81,981)
03/2003
03/27/2003WO2003025017A1 Cytokine receptor
03/27/2003WO2003025014A2 Use of peptides comprising post-translational modifications in the treatment of autoimmune pathologies
03/27/2003WO2003024993A2 Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assays
03/27/2003WO2003024973A1 Spirocyclic-6,7-dihydro-5h-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines
03/27/2003WO2003024971A1 6,7-dihydro-5h-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines
03/27/2003WO2003024970A1 Compounds which inhibit the release of inflammatory cytokines
03/27/2003WO2003024966A1 Pteridinone derivatives as modulators of chemokine receptor activity
03/27/2003WO2003024958A2 Processes for the preparation of 1,5-diaryl-3-substituted-pyrazoles
03/27/2003WO2003024936A1 Substituted pyrazolo compounds for the treatment of inflammation
03/27/2003WO2003024935A2 Substituted pyrazolyl compounds for the treatment of inflammation
03/27/2003WO2003024928A2 Novel aminoazetidine, -pyrrolidine and -piperidine derivatives
03/27/2003WO2003024926A2 Methods and compositions of novel triazine compounds
03/27/2003WO2003024924A1 Novel compounds and compositions as cathepsin inhibitors
03/27/2003WO2003024922A1 Hydroxyfattysulfonic acid analogs
03/27/2003WO2003024913A1 SUBSTITUTED BENZOIC ACID DERIVATIVES EXHIBITING NF-κB INHIBITING ACTIVITY
03/27/2003WO2003024486A1 Remedies for bone loss
03/27/2003WO2003024474A2 Anti-inflammatory agent
03/27/2003WO2003024473A2 Retinoid receptor pan-antagonists for stimulating chondrogenesis
03/27/2003WO2003024467A1 Compositions containing specific plants and drugs and foods for health use comprising the compositions as the active ingredient
03/27/2003WO2003024423A1 Apoptosis-mimicking synthetic entities and use thereof in medical treatment
03/27/2003WO2003024395A2 Linked biaryl compounds
03/27/2003WO2003024390A2 Hydroxyeicosenoic acid analogs
03/27/2003WO2003002553A3 Fluoropyrrolidines as dipeptidyl peptidase inhibitors
03/27/2003WO2003002058A8 Bone anabolic compounds and methods of use
03/27/2003WO2002096358A3 Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
03/27/2003WO2002094263A3 Caspase inhibitors and uses thereof
03/27/2003WO2002087496A3 Methods for inhibiting macrophage colony stimulating factor and c-fms-dependent cell signaling
03/27/2003WO2002083870A3 Pufa polyketide synthase systems and uses thereof
03/27/2003WO2002060859A3 Cyclic derivatives as modulators of chemokine receptor activity
03/27/2003WO2002053100A3 Pharmaceutical dosage form for oral administration of low molecular weight heparin
03/27/2003WO2002047705A3 Compositions containing an active fraction isolated from tricholoma conglobatum and methods of use
03/27/2003WO2002043738A3 Use of bisphosphonates for pain treatment
03/27/2003WO2002029060A3 Hematopoietin receptors hpr1 and hpr2
03/27/2003WO2002028844A1 Thiazole or oxazole derivatives
03/27/2003WO2002026774A3 Melanocortin receptor ligands
03/27/2003WO2002017880A3 Nitric oxide-producing hydrogel materials
03/27/2003WO2002012340A3 Transporters and ion channels
03/27/2003WO2002005857A3 Phosphatonin-related gene and methods of use thereof
03/27/2003WO2001092218A3 Polyamine analogues as therapeutic and diagnostic agents
03/27/2003US20030060873 Providing an electrochemical solution comprising metal and bioactive material; contacting electrochemical solution and substrate; forming a bioactive composite structure on substrate using an electrochemical procedure
03/27/2003US20030060629 Pyrazine derivatives as modulators of tyrosine kinases
03/27/2003US20030060619 Antibody for use in the disgnosis and treatment of kidney, urogenital, and sex disorders
03/27/2003US20030060613 Protein for use in the treatment of bone, tumor and inflammatory disorders
03/27/2003US20030060606 Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
03/27/2003US20030060515 Protein tyrosine kinase inhibitors for treating osteoarthritis
03/27/2003US20030060488 Drug comprising combination
03/27/2003US20030060473 Piperazine compounds as inhibitors of MMP or TNF
03/27/2003US20030060459 Diamines as modulators of chemokine receptor activity
03/27/2003US20030060455 Treating lung damage from smoke, endometriosis, Behcet's disease, ankylosing spondylitis, cancer, Lyme disease, and/or restenosis following agioplasty with 1-(4-t-butyl-phenyl)-3-(4-(6-morpholin-4-ylmethyl-peperidin-yl)naphthalen-1 -yl)-urea
03/27/2003US20030060452 N-heterocyclic derivatives as NOS inhibitors
03/27/2003US20030060410 Use of HMG fragments as anti-inflammatory agents
03/27/2003US20030059916 IRAK-4: compositions and methods of use
03/27/2003US20030059890 Protein for use as antiinflammatory, antiproliferative and antipyretic agents
03/27/2003US20030059871 Hematopoietin receptors HPR1 and HPR2
03/27/2003US20030059869 Novel G protein-coupled receptor, GAVE3
03/27/2003US20030059862 Antibodies against tumor necrosis factor delta (APRIL)
03/27/2003US20030059796 Detecting genes associated with controlling angiogenesis; obtain and culture endothelial cells, isolate ribonucleic acids, amplified or reduced concentrations of preferenial ribonucleic acids indicate association with angiogenesis
03/27/2003US20030059430 Use of peptides or small molecules in treatment of disease, in high-throughput screening, in use of metal-binding peptides derived from sequences present in CD74-homology domain of insulin-like growth factor
03/27/2003US20030059421 DNA encoding the baboon and cynomolgus macaque prostoglandin E2 receptor EP4 subtype
03/27/2003US20030059417 Methods and compositions for diagnosing and treating disorders involving angiogenesis
03/27/2003US20030059414 Cell populations which co-express CD49c and CD90
03/27/2003DE20218616U1 Therapeutic device, e.g. cushion, useful for alleviating rheumatism, gout or osteoarthritis, comprises cover filled with dried, crushed horse-chestnuts
03/27/2003CA2709442A1 Cell populations which co-express cd49c and cd90
03/27/2003CA2461074A1 Methods and compositions of novel triazine compounds
03/27/2003CA2461073A1 6,7-dihydro-5h-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines
03/27/2003CA2461072A1 Compounds which inhibit the release of inflammatory cytokines
03/27/2003CA2461071A1 Spirocyclic-6,7-dihydro-5h-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines
03/27/2003CA2460942A1 Substituted pyrazolyl compounds for the treatment of inflammation
03/27/2003CA2460808A1 Immune response associated proteins
03/27/2003CA2460719A1 Igf-binding protein-derived peptide or small molecule
03/27/2003CA2460704A1 Use of peptides comprising post-translational modifications in the treatment of autoimmune pathologies
03/27/2003CA2460544A1 Anti-inflammatory agent
03/27/2003CA2460358A1 Hydroxyfattysulfonic acid analogs
03/27/2003CA2460263A1 Hydroxyeicosenoic acid analogs
03/27/2003CA2460151A1 Cytokine receptor
03/27/2003CA2460125A1 Novel compounds and compositions as cathepsin inhibitors
03/27/2003CA2459949A1 Retinoid receptor pan-antagonists for stimulating chondrogenesis
03/27/2003CA2458720A1 Apoptosis-mimicking synthetic entities and use thereof in medical treatment
03/27/2003CA2429005A1 Substituted benzoic acid derivatives having nf-kb inhibiting action
03/27/2003CA2423885A1 Thiazole and oxazole derivatives
03/27/2003CA2357987A1 Genetic sequence related to bone diseases
03/26/2003EP1296142A2 Calcium receptor active molecules
03/26/2003EP1295939A1 Insulin-like growth factor binding protein
03/26/2003EP1295897A1 DNA encoding the chimpanzee prostaglandin E2 receptor EP4 subtype
03/26/2003EP1295880A1 Imidazole derivatives or salts thereof and drugs containing the derivatives or the salts
03/26/2003EP1295605A2 Method of increasing bone toughness and stiffness and reducing fractures
03/26/2003EP1294924A2 Method for identifying medically valuable active substances
03/26/2003EP1294874A2 Cd154 variants and uses thereof
03/26/2003EP1294871A1 Secreted epithelial colon stromal-1 polypeptides, nucleic acids encoding the same and uses thereof
03/26/2003EP1294765A2 Il-17 molecules and uses thereof
03/26/2003EP1294754A1 Interferon-alpha induced gene
03/26/2003EP1294752A2 Angiogenesis-modulating compositions and uses
03/26/2003EP1294740A2 Chemically-modified antimicrobial peptides, compositions and methods of production and use
03/26/2003EP1294728A1 HMG-CoA REDUCTASE INHIBITORS AND METHOD
03/26/2003EP1294724A1 Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents
03/26/2003EP1294721A1 Cyclic gmp-specific phosphodiesterase inhibitors
03/26/2003EP1294718A2 6,5-fused bicyclic heterocycles
03/26/2003EP1294716A1 Lactam inhibitors of factor xa and method
03/26/2003EP1294714A2 Thrombin receptor antagonists
03/26/2003EP1294711A2 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as as modulators of protein kinases
1 ... 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 ... 820